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The recent outbreaks of cholera in
Haiti, Pakistan, and Zimbabwe suggest
that our current global action plans
against cholera are failing. This issue
contains two important articles that will
help inform our discussions on ways to
respond to the global cholera situation.
Cholera is a severely dehydrating illness
caused by Vibrio cholerae, a Gram-negative
organism. V. cholerae exists in environmen-
tal aquatic reservoirs, and, as a result,
cholera is not an eradicable disease, but it
is controllable. Humanity has recognized
seven cholera pandemics since 1817, all
originating in Asia. The most recent
pandemic began in 1961 in Indonesia,
making it at half a century the longest
cholera pandemic on record. As opposed
to burning out after 5–20 years as all
previous pandemics have done, this pan-
demic, if anything, seems to be picking up
speed. Cholera outbreaks are occurring
with increasing frequency and severity, as
demonstrated by the recent major out-
breaks in Nigeria, Angola, Pakistan, Viet-
nam, Zimbabwe, and now Haiti. This is
on top of all the endemic infections that
largely go ‘‘unnoticed’’. In fact, cholera is
now endemic in approximately 50 coun-
tries worldwide, and V. cholerae infects 3–5
million individuals each year, killing ap-
proximately 100,000, only a minority of
whom die in outbreaks that garner media
attention.
Cholera can kill a healthy person within
12–24 hours of onset of diarrhea and can
cause explosive outbreaks; thus, it has the
ignominious distinction of probably being
the pathogen that can kill the most
number of humans in the shortest period
of time. Cholera outbreaks are associated
with chaos, and they severely stress health
care systems and communities. Human-
ity’s response to cholera led to the
development of oral rehydration solution
(ORS) and evidence-based approaches to
rehydration therapy. ORS perhaps repre-
sents the paradigmatic successful interface
of basic science and biomedical science
and a cost-effective, inexpensive public
health intervention. ORS costs pennies,
can be made locally or in a rural house,
requires minimal or no training for
production and administration, can be
used in extremely adverse circumstances,
and mitigates dehydrating illness and
death for all causes of diarrhea, not just
cholera. It is estimated that ORS has
saved the lives of 40 million individuals
since it was first endorsed by the World
Health Organization (WHO) in the 1980s.
In part because of this success of ORS,
response efforts to cholera over the last 30
years have largely focused on treating
individuals who become afflicted in the
short-term, and trying to provide safe
water and improved hygiene in the long-
term. However, as we mark a half century
for this pandemic, we must stop and ask: is
this still the best approach?
Despite heroic efforts by many, 13% of
the world’s population still lacks access to
safe water. To translate this statement, safe
water would have to be provided every
day for 10 years to an additional 240,000
people who currently lack safe water each
day to eliminate this disparity. And this
assumes that people with currently tenu-
ous access to safe water do not slip back-
ward, and that somehow we also provide
safe water to the 1–3 billion people who
will be joining us on the planet in the next
few decades. As such, the provision of safe
water to all of the world’s population is
truly a long-term solution, and one a
realist would say will take decades. A
second piece of data that needs to be
considered as we mark the 50th anniver-
sary of the start of this pandemic is that the
causative agent of our current pandemic is
different from those that caused the first
six pandemics. V. cholerae O1 can be
divided into two major biotypes. Earlier
pandemics for which we have data were
caused by what is referred to as the
‘‘classical’’ biotype, but the current pan-
demic is caused by the ‘‘El Tor’’ biotype.
Compared to classical organisms, V. cho-
lerae El Tor are much better at surviving in
the environment, and are more likely to
result in asymptomatic carriage in hu-
mans. The latter means that people can
introduce the infection into a new zone
unknowingly, and the former means that
once a zone is involved, it may well
become endemic for cholera. These facts
may explain in part why our current
pandemic extends much longer than all
previous ones. It also means that outbreaks
can be prolonged (as evidenced by Zim-
babwe), and that there will be no quick
fixes.
The El Tor variant has also undergone
two major modifcations over the last 20
years. First, an El Tor O1 strain acquired
a new lipopolysaccharide structure, form-
ing a new variant serotype, O139. Since
immunity to cholera is largely serotype
specific, this meant that a new variant had
evolved that could infect and kill individ-
uals thought to be immune to cholera by
previous exposure to O1. O139 spread
rapidly in the 1990s through 11 Asian
countries, but then was largely replaced by
its cousin O1 El Tor again (for unclear
reasons). More recently, El Tor has
undergone another genetic event to create
what is being referred to as a ‘‘hybrid’’
strain, an El Tor variant expressing
classical cholera toxin. Cholera caused by
the hybrid strain may be more clinically
severe, and the hybrid is rapidly replac-
ing the old El Tor strain in many areas.
The prevalence of the hybrid strain may
explain why we are seeing case fatality
rates of 1%–5% (or higher) in recent
outbreaks, as opposed to the ,1% histor-
ically accepted as the goal for response
teams.
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other tools that we can bring to bear to
control and respond to cholera? For
instance, V. cholerae passaged through the
human intestine is ‘‘hyperinfectious’’, and
this hyperinfectivity critically contributes
to V. cholerae’s ability to cause explosive
outbreaks. Could targeted or community-
wide administration of antimicrobials in
an initial phase of an outbreak sufficiently
undermine this contributing factor to alter
transmission dynamics? Such use of tetra-
cycline in the 1970s was not beneficial, but
would this still be the case if we used newer
and more potent drugs requiring only
single dose administration, such as azith-
romycin and doxycycline? What would be
the trade-offs? Such an approach could
easily drive drug resistance, but modeling
analysis of the risk-benefit ratio of such an
approach seems to at least be warranted.
Any benefit would presumably only be
temporary, and would not remove the
need for a more comprehensive response.
Few would argue that case detection,
rehydration therapy, and provision of safe
water and improved sanitation should be
cornerstones of any integrated response,
but should vaccination against cholera also
be part of this response? Historically, the
role of cholera vaccine has been contro-
versial. Opponents to the use of cholera
vaccine have largely said that in the chaos
of a cholera outbreak, the majority of
resources should focus on rehydration and
provision of safe water and improved
sanitation. The old parenteral cholera
vaccine required multiple immunizations,
had a high adverse event profile, and at
best was moderately protective for few
months. But with the development of
improved (albeit not perfect) cholera
vaccines, the emergence of prolonged
outbreaks, and the endemic nature of El
Tor cholera in so many areas of the world,
it may be time to revisit this decision tree.
There are currently two oral cholera
vaccines licensed and being manufactured
in the world. Both are oral vaccines that
contain killed V. cholerae organisms from
different strains. One (Dukoral, Crucell)
provides protection against V. cholerae O1
and contains a non-toxic B subunit of
cholera toxin. It requires administration
with buffer. The vaccine is approved for
use over the age of 2 years, is WHO-pre-
qualified, has been administered to over a
million individuals, is safe and immuno-
genic, requires two or three administra-
tions depending on age and previous
exposure, and provides both direct and
herd protection of 70%–90% in the 6
months following vaccination, and ap-
proximately 50% protection over 2–3
years. A bivalent O1 and O139 oral killed
cholera vaccine is produced locally in
Vietnam (mORC-VAX, VaBiotech,) and
is currently being produced as Shanchol
by Shantha Biotechnics in India for inter-
national distribution. Pre-qualification of
the vaccine is being considered by the
WHO. Shanchol and mORC-VAX are
administered as 1.5 ml of fluid to be
followed by safe water, is approved for
use over the age of 1 year, is administered
as one or two doses, and is as effective of
Dukoral, with some suggesting that it may
provide longer protection of up to 3–5
years, especially in endemic zones. It has
not been field-evaluated in non-endemic
zones.
The WHO position statements on the
use of cholera vaccines have been evolving
over the last 20 years. The initial position
was that efforts should focus on treating
patients with cholera and providing safe
water and improved sanitation. The 2001
position statement suggested that cholera
vaccine could be deployed as part of a
program of response in endemic zones,
but that oral killed cholera vaccine may
have limited efficacy during epidemic
or outbreak responses. The most recent
WHO position statement of 2010 further
suggests that cholera vaccine should be
used in endemic settings or in predictable
situations, and suggests that the vaccine
could be considered in reactive situa-
tions (that is during an outbreak that has
already started), but that data for such use
are lacking and needed [1]. It is in this
context that the two reports in the current
issue of PLoS Neglected Tropical Diseases make
significant contributions. The report by
Reyburn et al. [2] describes the modeling
of the effect of cholera vaccine once an
outbreak has occurred using data from a
number of recent outbreaks. The research-
ers modeled 50% and 75% vaccine
coverage, with completion of vaccination
ranging from ‘‘rapid’’ (10 weeks after an
outbreak was first reported), to a ‘‘maxi-
mum’’ of completion of vaccination 33
weeks after an outbreak is first reported.
The researchers found that even delayed
responses could have benefit, and their
model neither included herd effect modi-
fiers, nor the effect that vaccination could
have on subsequent disease burden after
the initial outbreak has waned into an
endemic situation. This issue also contains
a report by Anh et al. [3] describing a
case-control study of the reactive use of
the Vietnamese killed cholera vaccine
during a significant outbreak in Hanoi,
an endemic zone. Administration of one
or two doses of the vaccine was found
to provide approximately 76% protective
efficacy after controlling for additional fac-
tors. The only previous report of reactive
cholera vaccine use was an observational
study in Micronesia using an oral live
attenuated cholera vaccine, and in that
situation, the vaccine was also asso-
ciated with approximately 80% protective
efficacy.
These reports are significant, and will
contribute to the discussion on the role
that cholera vaccine could play in both
short- and long-term response plans. What
role cholera vaccine will play, if any, is still
uncertain, and even if cholera vaccine is
incorporated into response plans, many
logistic hurdles would remain (who will
pay, will vaccine be stockpiled, which
vaccine would be used, who would control
its use, delivery, and deployment, how will
a vaccine program synergize with other
response efforts and immunization efforts,
etc.). But one thing is very clear as we
mark the 50th anniversary of the start of
our current war with cholera: we have a
wily and adaptive foe that has changed the
rules of engagement repetitively, and it
may be time for us to similarly adapt our
strategies.
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